Edition:
United States

Retrophin Inc (RTRX.O)

RTRX.O on Consolidated Issue listed on NASDAQ Global Market

18.49USD
23 May 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$18.49
Open
$18.22
Day's High
$18.66
Day's Low
$17.76
Volume
338,732
Avg. Vol
376,059
52-wk High
$33.00
52-wk Low
$17.53

Latest Key Developments (Source: Significant Developments)

Retrophin Reports Fourth Quarter And Full Year 2018 Financial Results
Tuesday, 26 Feb 2019 04:01pm EST 

Feb 26 (Reuters) - Retrophin Inc ::RETROPHIN REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.18.Q4 EARNINGS PER SHARE ESTIMATE $-0.48 -- REFINITIV IBES DATA.Q4 ADJUSTED NON-GAAP LOSS PER SHARE $0.21.TOP-LINE RESULTS FROM PIVOTAL PHASE 3 FORT STUDY IN PKAN EXPECTED IN 3Q 2019.NET PRODUCT SALES FOR Q4 OF 2018 WERE $43.8 MILLION, COMPARED TO $42.2 MILLION FOR SAME PERIOD IN 2017.Q4 EARNINGS PER SHARE VIEW $-0.48, REVENUE VIEW $44.5 MILLION -- REFINITIV IBES DATA.  Full Article

Retrophin Says FDA Accepts NDA Filing For New Formulation Of Thiola
Monday, 12 Nov 2018 07:00am EST 

Nov 12 (Reuters) - Retrophin Inc ::RETROPHIN ANNOUNCES U.S. FDA ACCEPTANCE OF NDA FILING FOR THE NEW FORMULATION OF THIOLA® (TIOPRONIN) IN THE TREATMENT OF CYSTINURIA.RETROPHIN INC - FDA HAS ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF JUNE 30, 2019..  Full Article

Retrophin Prices Upsized $240 Million Convertible Senior Notes Offering
Wednesday, 5 Sep 2018 08:31pm EDT 

Sept 5 (Reuters) - Retrophin Inc ::RETROPHIN PRICES UPSIZED $240 MILLION CONVERTIBLE SENIOR NOTES OFFERING.AGGREGATE PRINCIPAL AMOUNT OF THE OFFERING WAS INCREASED FROM THE PREVIOUSLY ANNOUNCED OFFERING SIZE OF $200 MILLION.  Full Article

Retrophin Q2 Loss Per Share $0.56
Thursday, 26 Jul 2018 04:05pm EDT 

Retrophin Inc ::RETROPHIN CHIEF EXECUTIVE OFFICER STEPHEN ASELAGE ANNOUNCES HIS DECISION TO RETIRE.RETROPHIN REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND ANNOUNCES CEO TRANSITION PLAN.Q2 LOSS PER SHARE $0.56.BOARD OF DIRECTORS INITIATES SEARCH FOR SUCCESSOR.Q2 ADJUSTED NON-GAAP LOSS PER SHARE $0.25.Q2 EARNINGS PER SHARE VIEW $-0.35 -- THOMSON REUTERS I/B/E/S.PHASE 2 PROOF-OF-CONCEPT STUDY OF CNSA-001 IN PATIENTS WITH PKU SET TO INITIATE.NET PRODUCT SALES FOR Q2 OF 2018 WERE $41.3 MILLION, COMPARED TO $38.8 MILLION FOR SAME PERIOD IN 2017.  Full Article

Retrophin Q1 Loss Per Share $0.46
Tuesday, 1 May 2018 04:01pm EDT 

Retrophin Inc ::RETROPHIN REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.46.Q1 REVENUE $38 MILLION VERSUS I/B/E/S VIEW $39.3 MILLION.Q1 ADJUSTED NON-GAAP LOSS PER SHARE $0.14.Q1 EARNINGS PER SHARE VIEW $-0.45 -- THOMSON REUTERS I/B/E/S.PIVOTAL PHASE 3 DUPLEX STUDY OF SPARSENTAN IN FSGS UNDERWAY TO SUPPORT SUBPART H NDA FILING.AS OF MARCH 31, 2018, COMPANY HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $264.1 MILLION.  Full Article

Retrophin Expects Total Net Product Sales Of Approximately $155 Million​ In 2018
Monday, 8 Jan 2018 07:00am EST 

Jan 8 (Reuters) - Retrophin Inc ::RETROPHIN PROVIDES CORPORATE UPDATE AND 2018 OUTLOOK.‍FOR FISCAL YEAR 2017, COMPANY EXPECTS TOTAL NET PRODUCT SALES OF APPROXIMATELY $155 MILLION​.‍COMPANY EXPECTS NET PRODUCT SALES FOR Q4 OF 2017 TO BE APPROXIMATELY $42 MILLION​.‍COMPANY EXPECTS A NEW DRUG APPLICATION FILING IN 2018 FOR ITS NEW FORMULATION OF THIOLA FOR TREATMENT OF CYSTINURIA.  Full Article

Retrophin Enters Into Future Acquisition Right, Joint Development Agreement With Censa Pharma
Friday, 5 Jan 2018 09:05am EST 

Jan 5 (Reuters) - Retrophin Inc ::RETROPHIN SAYS ON DEC 16, CO ENTERED INTO FUTURE ACQUISITION RIGHT, JOINT DEVELOPMENT AGREEMENT WITH CENSA PHARMA - SEC FILING.RETROPHIN SAYS IF CO EXERCISES OPTION TO BUY CENSA, COMPANY WILL HAVE TO PAY $65 MILLION IN UPFRONT CONSIDERATION.RETROPHIN - ‍AGREED TO FUND CERTAIN DEVELOPMENT ACTIVITIES OF CENSA'S CNSA-001 PROGRAM IN AMOUNT EXPECTED TO BE ABOUT $16 MILLION THROUGH PROOF OF CONCEPT​.RETROPHIN - ALSO ‍HAS RIGHT TO ACQUIRE CENSA ON TERMS AND SUBJECT TO CONDITIONS SET FORTH IN A SEPARATE AGREEMENT AND PLAN OF MERGER​.  Full Article

Retrophin And Censa Pharmaceuticals Enter Into Strategic Collaboration To Advance Cnsa-001
Friday, 5 Jan 2018 08:00am EST 

Jan 5 (Reuters) - Retrophin Inc ::RETROPHIN AND CENSA PHARMACEUTICALS ENTER INTO STRATEGIC COLLABORATION TO ADVANCE CNSA-001 FOR THE TREATMENT OF PHENYLKETONURIA (PKU).RETROPHIN INC - ‍UNDER DEAL TERMS , CO IS MAKING A $10 MILLION UPFRONT PAYMENT TO CENSA AND WILL PROVIDE FUNDING FOR DEVELOPMENT OF CNSA-001 IN PKU​.RETROPHIN - UNDER DEAL TERMS, ‍CENSA WILL RUN DEVELOPMENT PROGRAM FOR CNSA-001​, WHICH WILL BE CONDUCTED UNDER OVERSIGHT OF A JOINT STEERING COMMITTEE.  Full Article

Retrophin reports third quarter 2017 financial results
Tuesday, 7 Nov 2017 04:21pm EST 

Nov 7 (Reuters) - Retrophin Inc :Retrophin reports third quarter 2017 financial results.Q3 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.Q3 loss per share $0.46.Q3 adjusted non-GAAP earnings per share $0.15.  Full Article